About the Company
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AGLE News
Aeglea BioTherapeutics (NASDAQ: AGLE)
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other ...
Spyre Therapeutics Enhances Protection for Executives and Board
Spyre Therapeutics, Inc. has introduced a new indemnification agreement for its board members and executive officers, replacing previous arrangements from its predecessor, Aeglea BioTherapeutics ...
Spyre Therapeutics Inc (SYRE)
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced new positive phase I/II data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D), a rare genetic disease. The ...
Spyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-Market
Spyre Therapeutics, Inc. (SYRE), a company focused on inflammatory bowel disease on Monday said it entered into a deal for a private ...
Lilly Ventures Fund I LLC's Net Worth
Who is Lilly Ventures Fund I LLC? Lilly Ventures Fund I LLC has an estimated net worth of $18 Million. This is based on reported shares across multiple companies, which include Coherus BioSciences ...
SAB Biotherapeutics Inc SABS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis ...
Northwest Biotherapeutics Inc NWBO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 Iovance Biotherapeutics Inc Earnings Call
Sara Pellegrino; Senior Vice President, Investor Relations and Corporate Communications; Iovance Biotherapeutics Inc Frederick Vogt; Interim President and Chief Executive Officer; Iovance ...
Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...
Loading the latest forecasts...